INTRODUCTION
============

Prostate cancer is the most frequent cancer among men in Sweden, representing 32.2% of all cancer forms, with an annual increase of 0.7% in the last 10 years \[[@R1]\]. The total five-year survival rate of prostate cancer was 87.3% in 2009 \[[@R2]\], which means that most men survive cancer and treatment. In Sweden, there is a consensus about non-screening, but in a long-term study over 15 years Bill-Axelsson *et al.* found that a localized and well differentiated tumour treated with radical prostatectomy, RP, versus watchful waiting, reduced the rate of deaths by 14.6% compared to 20.7% respectively \[[@R3]\]. This implies that more lives may be saved by detection and treatment. International research has shown \[[@R4]\] that even if life is prolonged, problematic symptoms are presented over the years following treatment.

The most common treatment options offered to men are radical prostatectomy, external beam radiation, brachytherapy and active surveillance. For the patients, it may be difficult to choose between treatment options, especially for those with an early-stage prostate cancer \[[@R5]\], since all treatments have side effects such as bowel problems connected with beam radiation \[[@R6]\] and radical prostatectomy with urinary and sex life problems \[[@R7]\]. Symptoms following radical prostatectomy may overlap general ageing problems such as fatigue, decreased mobility and insomnia. Fatigue is a well-known general adverse treatment-related side effect of cancer and, Fransson found increased problems with fatigue from pre-treatment up to five years post radiation treatment in a sample of men with prostate cancer (n=407). If fatigue is presented to a similar degree in men treated with RP was not investigated. Impaired mobility and insomnia are phenomena described in relation to cancer illnesses and old age, and Stenholm *et al.* found impaired mobility correlating to insomnia in a Finnish population study of 2 825 men of 55 years of age and older \[[@R8]\]. The authors, however, did not clearly differentiate between possible origins, and there are national differences between countries. Treatment options for prostate cancer are continually improving, and whether a south Swedish sample presents similar problems is not known.

Quality of life is described by Aaronson *et al.* as a multidimensional concept that covers life functions, specific symptoms and overall global health \[[@R9]\]. Although referring to patients with cancer, the core concept is general and gives a subjective view on persons' life quality. The underlying assumption is that there may be a presence of symptoms and still high ratings for quality of life. Quality of life assessments are often used as tools for predicting and describing treatment outcomes and how life is perceived after treatment. It has been shown earlier that high ratings for quality of life may follow in the wake of cancer treatment \[[@R10]\].

Treatment affects quality of life in patients with cancer. Abraham *et al.* found that most men 93% (n=1 542) were satisfied with their choice of treatment (prostatectomy) indicating a non-significant trend toward time dependence, i.e. that symptoms of illness decreased over time \[[@R11]\]. Short-term satisfaction was connected to *e.g.* post-surgery symptoms such as indwelling urinary catheter treatment and long-term satisfaction, *e.g.*long time after surgery, was more often connected to urinary and sexual function \[[@R12]\]. Since the treatment choice affects life and quality of life for the rest of the men's lives, it is a challenging task for the health professions to monitor and handle cancer and treatment sequels according to evidence based medicine.

AIM
===

The aim of our study was in threefold, including 1) identifying change in domains of functioning in patients from baseline to five years after treatment, and 2) identifying important factors influencing their QOL ratings over five years measured with the EORTC QLQ C-30 and PR-25, and 3) investigating the impact of increasing age, unemployment *vs* employment and marital status (having a partner) on their quality of life across time.

Specific research questions answering the objectives:

1.  ^[1](#FN1){ref-type="fn"}^ What aspects on quality of life ^[2](#FN2){ref-type="fn"}^ as assessed by the EORTC QLQ C-30 show significant change from baseline to five years, and what aspects from the PR-25?

2.  What aspects of functioning and symptoms from the EORTC QLQ C-30 and the PR-25 influence quality of life ^[3](#FN3){ref-type="fn"}^ ratings over the years?

3.  Is there an effect on quality of life ^[3](#FN3){ref-type="fn"}^ at five years from increasing age, unemployment *vs* employment and whether or not living with a partner?

MATERIAL AND METHODOLOGY
========================

Study Design
------------

A prospective, longitudinal survey design was used, and data was collected at six points: pre-treatment (baseline), 3 months after RP, 1-3 and 5 years after RP.

Participants
------------

Inclusion criteria included Swedish-speaking men diagnosed with localized prostate cancer (LPC), regardless of age, with no signs of impaired brain function and eligible for radical prostatectomy between the years 2000 and 2007, and referred to a department of Urology in southern Sweden. The men were consecutively asked to participate in the longitudinal study. A total of 222 men accepted. By the end of the data collection period, December 2011, a total of 167 men remained in the study. The clinical treatment procedure consisted of radical retropubic prostatectomy in all cases with a nerve-sparing technique where appropriate and possible.

Data Collection
---------------

During the recruitment period, consecutive eligible patients were verbally invited to participate in the study by a specialist urological nurse. A consent form and the first questionnaire (baseline) were handed out to all the participating patients. The patients were asked to complete the baseline questionnaire at home and a pre-paid return envelope accompanied the questionnaire. On the following data collection occasions, the questionnaires and pre-paid return envelopes were sent by mail-out-mail-in procedure and this was repeated at 3 months, 1, 2, 3 and 5 years.

Questionnaires
--------------

To determine factors under study, the Health-Related Quality of Life questionnaires, QLQ C-30 and the Prostate cancer specific, QLQ PR-25 were used for assessment. The questionnaires were developed for measurement of quality of life in cancer patients \[[@R9]\], and for specific prostate cancer symptoms \[[@R13]\], respectively, where at least a 10 point difference in scoring is clinically interesting \[[@R14]\]. The 30 variables of the QLQ C-30 explore physical, emotional, cognitive, role and, social functioning and quality of life, all arranged in a Likert scale format. Also included are multi-item variables of fatigue, nausea/vomiting and pain, together with single items assessing dyspnoea, appetite loss, constipation, financial impact and diarrhoea. All variables are transformed into scales and further into separate indexes and, all indexes are summarized into a concept of quality of life. Chronbahs' alpha has been described between 0.52 to 0.89 for the instrument \[[@R9]\]. The prostate-specific module, PR-25, is developed for prostate cancer and is to be used in connection with the QLQ C-30. The instrument consists of 25 variables in Likert scale format. The variables assess sexual activity and functioning, urinary, bowel and hormonal treatment-related problems and the frequency of using incontinence aids. All variables are transformed into scales and further into separate indexes and, all indexes are summarized into a health status presenting life with prostate cancer. Chronbachs' alpha has been described between 0.30 to 0.86 for the instrument \[[@R13]\]. Raw scores for the QLQ C-30 and the PR-25 were transformed into a 100-point scale \[[@R15]\], where functional scales with high ratings represent high functioning, except for scales of fatigue, pain and, nausea/vomiting where low scores represent a low grade of problems, *i.e*. a high grade of functioning. For single item scores, lower scores represent better functioning, *i.e.* few symptoms and problems.

### Statistical Analysis

To answer study-specific questions (1, 2, 3) the following statistical procedures were performed:

1.  Differences in categorical data, both in the nominal and ordinal scale levels, were tested with the Chi-square test. Differences in mean ratings of all variables across the data collection period (five years) were tested with one-way analysis of variance. When significant ANOVA was found, the Bonferroni post hoc conservative analysis was applied due to rather small subgroups to avoid mass significance \[[@R16],[@R17]\]. Pearson's correlation was applied to determine associations between demographic data, numerical variables and, between the questionnaire variables under study.

2.  The outcome on QOL ratings from the questionnaires was determined using a multiple regression analysis model. The analysis model explains how much of the variation in QOL ratings can be explained by the variables, and the contribution of each questionnaire variable. The test uses a quantitative dependent variable (QOL) and predicts the influence from one or more independent variables. In this study, all variables were included in the model (enter method) except two from PR-25, due to the requirement of not using highly correlated variables (\>0.7-0.9) in the analysis \[[@R18]\]. Thus, the created model estimated the degree to which QOL variation was explained by the subscales in the model. Before creating a model, a correlation analysis was done and relationships among the variables established. Correlations did not exceed 0.7-0.9 in a bivariate correlation, thus indicating no multicollinearity. The multicollinearity was further checked for by collinearity diagnostics where a tolerance value \>0.1 and a VIF (Variance inflation Factor) value \<10 indicated no multicollinearity, i.e. a linear correlation that makes it possible to distinguish between variable influences \[[@R19]\].

3.  Whether there was an influence on quality of life in general, from increasing age, unemployment *vs* employment and whether or not living with a partner at five years was tested by a logistic regression analysis. Early or late symptoms was used as the dependent dichotomised variable (baseline=0, 5 years=1). The model was tested by the Hosmer-Lemeshow goodness-of-fit test. Cox and Snell R Square and Nagelkerke R Square values indicated the amount of variation in the dependent variables that was explained by the model \[[@R18]\]. All questionnaire variables were included in our study model, together with age (continuous variable), living with a partner (no==0, yes=1), still working or not (no=0, yes=1).

The study was approved by the Ethical Committee, The medical Faculty at Lund University (U451-01).

RESULTS
=======

At baseline, 222 men accepted to participate in the study. Of the 222 men, 167 (75.2%) men were still included in the study after five years (Table [1](#T1){ref-type="table"}).

Patient Characteristics
-----------------------

The study participants were aged 36 to 75 years, most men were married 181/222 (82.0%) and 93/222 (42.0%) had an educational level of post-compulsory school. Some men were retired, 86/222 (39.0%) while 56/222, (25.2%), were still in active employment.

### Changes in quality of life from baseline to five years

#### Health-Related Quality of life, EORTC QLQ C-30

Results for the QLQ C-30 scale (Table [2](#T2){ref-type="table"}) show physical, role and cognitive functioning scales rated as highly functioning at baseline and at 3 months (mean 96.3-90.4) and at five years with no fluctuation over the years (p=0.11-0.98). Emotional functioning showed a low degree of functioning at baseline, (mean 78.9) and a significant increase over the years to 90.9 in year five (p=\<0.00). Social functioning was rated high at baseline (mean 92.4) with a decrease at 3 months (mean 86.3) and a return to high social functioning at five years (mean 92.2, p=\<0.003).

QOL was rated at 78.1 points at baseline and lower after three months, 77.0. At five years, QOL had increased to an above-baseline rating, 80.4, though this increase was not significant (p=0.27).

Patients reported the least problems for fatigue (mean 10.3), nausea/vomiting (mean 1.3) and, pain at baseline. At five years, problems with nausea/vomiting and fatigue had increased, though not significantly. Problems with pain had slightly decreased at five years (ns).

In single-symptom scales for ratings of dyspnoea, sleep, appetite, constipation, diarrhoea and economy impact, most problems were scored for sleep (17.3) and dyspnoea (12.1), at baseline. At five years, ratings for sleeping problems had slightly decreased (ns) and for dyspnoea slightly increased (ns). Ratings for remaining single symptoms were still rated low at the 5-year assessment (ns).

#### Prostate Cancer Specifics, PR 25

Ratings for the PR-25 questionnaire (Table [2](#T2){ref-type="table"} cont.) for sexual activity showed a non-significant decrease over the five years, 48.4 - 40.4 (p=0.25), whereas sexual functioning decreased between baseline and 3 months (p=\<0.00) and was even lower at year five 56.7, (p=\<0.00). Urinary problems scored the highest at baseline (17.1) and over time (16.2), and they did not decrease over time (p=0.27). Bowel symptoms rated low at baseline and over time, and did not decrease over time, 4.1 - 4.5, (p=0.06).

Side effects from surgery, such as those after hormonal treatment, were rated 6.2 points at baseline and increased significantly both at three months (11.0 p=\<0.00) and after five years (9.5 p=\<0.00).

The use of incontinence aids showed an increase after three months, from 13.3 to 22.9, and the increase had levelled out at year 5 (p=0.06).

### Influences on quality of life over the years from functioning and symptoms

The multiple regression analysis (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}) estimating influences on QOL from other variables in the C-30 and PR-25 at five years showed significant values for nausea and vomiting (p=\<0.00), emotional (p=\<0.00) and social functioning (p=\<0.01) and pain (p=\<0.0.02). All independent variables (functional and single items variables) were entered into the model at once, since the Pearsons' correlation showed correlations between 0.45-0.10. The results show how well the variables, as a set and individually, predict the effect on quality of life. No multicollinearity was found. Two outliers were identified with standardized residuals of 3.7 and 3.8, respectively. Coook's distance showed no undue influence from these cases, 0.3, suggesting no large problem and they were thus not excluded. The model as a set explained 46.1% of the variance with a significance value of p=\<0.00

The impact on QOL from variables in the PR-25 (Table [5](#T5){ref-type="table"}) showed that lack of hormone-related symptoms contributed significantly (p=\<0.00) to QOL. The scales of bowel problems, PRBOW, and urinary aids, PRAID, had to be excluded to make a significant model. No multicollinearity was found between sexual activity, sexual functioning, urinary functioning and hormone-related symptoms. The model as a set explained 23.5% of the variance.

### Influence on quality of life presented at five years

The logistic regression (Table [5](#T5){ref-type="table"}) was performed to answer the question of what problems were present after five years. Three independent areas were reported, emotional (p=\<0.00), social functioning (p=\<0.00) and fatigue (p=\<0.00). The model contained all 15 independent QLQ C-30 variables (Table [3](#T3){ref-type="table"}) and was statistically significant (χ^2^15, n=222) 58.45, p\<0.00, showing that the model was able to distinguish between early and late symptoms. The model explained 23.0% (Cox and Snell R square) and 30.6% (Nagelkerke R square) of the variance and correctly classified 75.0% of the cases. We noticed that there were no significant differences between baseline and five years in the ANOVA analyses for fatigue symptoms, while there were differences regarding emotional functioning as well as social functioning. For further correction, the goodness of fit test, Hosmer-Lemeshow test \[[@R16]\] was established with a p value of 0.189 representing an acceptable model.

In the PR-25 module, none of the six scales showed any significant results in the multivariate analysis when tested with baseline *vs* five years as the dependent variable. Goodness of fit was established by Hosmer-Lemelshow test with a p value of 0.292 representing an acceptable model. However, in the ANOVA analysis, sexual function and hormonal treatment-related symptoms showed significance *i.e.*more problems after five years. Adding variables such as living with a partner and employment status did not significantly affect the results concerning the variables in QLQ-30, nor the variables in the PR-25 module.

DISCUSSION
==========

Our study investigated a population of patients with localized prostate cancer before and five years after retropubic prostatectomy. Patients represented a relatively young group of men (mean 62 years), considering that the mean age at the time of diagnosis in Sweden is 75, and this may have influenced the ratings positively. Younger men may be more prone to repeatedly complete questionnaires over a number of years. Huang determined that age at diagnosis, time from treatment and primary treatment were predictors of QOL in all treatments affecting urinary and sexual functions. In their study, problems occurred immediately after radical prostatectomy and returned to baseline after two years \[[@R20]\]. This fluctuation is not presented in our study, where problems remained and worsened over the years, *i.e.*regarding sexual functioning. The questionnaires are well-known and have shown high internal and external validity in a large number of studies. The QOL PR- 25 has been applied to prostate cancer study results for almost a decade now and is used as a cancer-specific complement to the EORTC QLQ C-30 questionnaire. Van Andel *et al.* stated discriminability between the two scales meeting criterion for construct validity \[[@R13]\]. It is to be noted there was a large rate of internal dropouts in the PR 25 variables. The reason for this is unknown to us and is not further looked into in this study. The phenomenon calls for further investigation.

There are some study limitations to be considered. Over the years, the patients were not followed in the study regarding further treatment and occurrence of co-morbidity. Whether or not everyday living was further affected by the prostate cancer and its treatment, or by other aspects from living, could not be established. However, quality of life was rated high, and problems stated after five years could reasonable be present in the wake of prostate cancer treatment or have other causes.

Patient-reported outcome of QOL did not differ over the five years of data collection. The result is comparable to other population studies that have shown similar ratings for QOL, e.g. Jakobsson, Lovén, Hallberg (2004) and Michelsson *et al.* (2000). In a study by Bach *et al.* \[[@R21]\], ratings for QOL decreased post-operatively, which they did not do in our study. Our study represented a somewhat younger group of men with a wider age range (36-75 years). Fransson *et al.* investigated patients given endocrine treatment with or without radiotherapy and found results comparable to ours and with no differences in quality of life after four years \[[@R22]\]. Endocrine treatment is otherwise known to affect bowel and sexual functioning negatively and radiotherapy is known to give bowel problems \[[@R23]\]. Patients in our study may have had endocrine or radiotherapy treatment which explains the reported problems from symptoms resembling hormonal treatment symptoms. The urinary and bowel problems also appear among men after RP, which makes our study results comparable. Our results are also similar to results from QOL ratings from a normative sample of the Swedish population established by Michelson *et al.* \[[@R24]\]. Thus, it may be interpreted from our study results that prostate cancer is not significantly affecting QOL in physical aspects.

Emotional functioning showed low ratings at baseline and a significant increase over the five years. This is consistent with Bach *et al.* \[[@R21]\] who reported similar figures at baseline and an increase after surgery. Wallace *et al.* reported emotions from getting the diagnosis message in a qualitative study of prostate cancer survivors as 'shock', 'body blow', 'fear' and 'anger', emotions that may well be reactions in connection with the presentation of a cancer diagnosis \[[@R25]\]. Jakobsson *et al.* \[[@R26]\] presented similar results among cancer survivors, and it is reasonable to assume that patients in our study do not differ from other men in the same situation, and this would explain the increased ratings of emotional functioning after treatment and over the years.

Social functioning decreased at three months and increased over the years. This may be an effect of post-surgery conditions in general, together with catheter-treatment side effects that are known to make patients stay at home and withdraw from social life during the treatment period \[[@R27]\]. The high physical, role, and cognitive functioning ratings over the five years with no fluctuations, may be connected to the men's age and good physical condition in general. It may be concluded that the men managed to handle the impact from surgery in a way that seemed not to adversely affect their daily life in these aspects.

Most single individual item symptoms did not change after surgery, and the highest scores, representing most problems, were found for sleeping problems and dyspnoea. Ratings did not decrease over time and the origin of the problems may not primarily be surgery or cancer, but connected to other problems. Thus, our results are similar to those of Fransson *et al.* \[[@R22]\], who found increased problems after four years among men who had external beam radiotherapy. They also found that emotional functioning and dyspnoea mostly affected QOL.

In a study by Erickson and Berger (2011) on patients with non-specified cancer, old age and anxiety were reasons for sleeping disorders. However, these problems may be present in a general population at times. Cancer-related symptoms, apart from anxiety, such as pain, cough and dyspnoea, as well as treatment-related factors, are described \[[@R28]\] as being similar to those for patients in our study. The connection between sleeping disorder and dyspnoea may be due to coughing and shortness of breath, as well as stemming from malignant disorders, and this study is not conclusive on this issue. Gupta *et al.* (2007) found that dyspnoea was a strong predictor for quality of life in patients with different cancer types, regardless of patient age and treatment \[[@R29]\]. This finding is not similar to our results. Gupta *et al.* suggest a longitudinal study design to confirm the association over time. Our study, over five years, shows lower ratings of dyspnoea at baseline than in that of Gupta *et al.* and displayed no difference in ratings over time.

Even though fatigue is a well-known adverse consequence of cancer and cancer treatment reported by Fransson and Gupta *et al.* for example \[[@R6],[@R29]\], initial scoring from our study showed lower figures for fatigue than for sleeping and dyspnoea problems. In the multivariate analyses, fatigue was not found to make a significant impact on QOL after five years. Whether fatigue was due to the cancer disease or not is not stated here.

Ratings of sexual activity and functioning from 3 months onwards decreased significantly post-surgery and decreased further in year five. A waning sexual functioning after prostate cancer treatment is in line with earlier study results and may be due to surgery techniques and post-surgery *per se* \[[@R30]\]. With regards to the relatively young age distribution of patients, it is surprising to find that sexual activity and functioning are not closer to baseline scores after five years. Also surprising is that sexual activity results did not decrease while sexual functioning did. This may be due to side effects from surgical techniques of nerve sparing but is also unexpected considering all modern pharmacological and technical aids on the market. Patients may be reluctant to give a truthful answer or to overestimate their self-rated ability. The highest internal dropout rates are in sexual and urinary areas of the questionnaires. Considering that no sexual functioning variables showed up significantly in the multivariate analyses, it is reasonable to assume that a sexual life was regarded less important than having survived the cancer disease.

Urinary problems and the use of incontinence aids increased in three months and decreased to baseline levels in five years, probably linked to a period of reduced catheter treatment and fewer leaking problems \[[@R30]\].

Clinically, the findings of this study call for nurses to better assess and focus on physical health problems of cancer patients when they have undertaken surgery and at follow up visits they need to pay more attention to emotional and social aspects of life, in addition to caring for pain, fatigue, nausea, and vomiting resulting from the surgery. Patients need information on problems that are present at that time and may not even remember having been given information if it was not called for. To be able to make a difference in the patient's post-surgical life, nurses need the ability to bridge the gap between in-hospital treatment and everyday life. In-hospital nurses may therefore need to make an extra effort in reporting patient status and life situation to community care nurses and not just the medical status in purpose to meet patients' needs.

CONCLUSIONS
===========

QLQ areas mostly affected after surgery, at five years in relation to baseline, were positive effects on emotional and social functioning. The most outstanding impacts on QOL after five years were emotional and social functioning and lack of fatigue and nausea and vomiting. Most likely affected QOL ratings, though in positive way, were aspects of increased emotional and social functioning and lack of fatigue.

Sexual activity and functioning decreased after surgery and were not regained over the years, but did not negatively affect QOL. Emotional functioning and sexual activity presented a 10-point increase and decrease, respectively, and are therefore clinically most interesting according to our suggested interpretation. Problems were not increasing with increasing age, or whether living with a partner or not. The overall interpretation is that symptoms of illness and post-treatment shortcomings differed over time, but they did not affect QOL in a longitudinal perspective. It was interpreted that psychological aspects of life, such as emotional and social functioning, bridged physical shortcomings and contributed to a high quality of life. The finding supports and legitimizes the theoretical framework underpinning the study.

Figures refer to the result section
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###### 

Characteristics of participants at baseline (n =222).

  Variables                                                  
  ---------------------------------------------------------- --------------
  *Age*                                                      62.7 (6.09)
  Year, m, (sd)                                              36 -- 75
  Range 36 - 75                                              
  *Living with partner ^[1)](#T1F1){ref-type="table-fn"}^*   
  Yes                                                        181
  No                                                         19
  *Educational level*                                        
  \<Compulsory school                                        
  Compulsory school                                          93
  Post-Compulsory below University level                     48
  University level                                           25
  Others                                                     34
  *Employment status*                                        
  Working                                                    56
  Retired                                                    86
  On sick leave                                              2
  Disability pension                                         6
  Others                                                     7
  *Tumour stage*                                             
  T1 B                                                       2 (1%)
  T1 C                                                       44 (65%)
  T2                                                         73 (33%)
  T3                                                         3 (1%)
  *Gleason score*                                            
  3                                                          5 (2%)
  4                                                          24 (11%)
  5                                                          40 (18%)
  6                                                          80 (36%)
  7                                                          60 (27%)
  8                                                          9 (4%)
  9                                                          2 (1%)
  *PSA*                                                      
  Mean                                                       7.7
  Range                                                      0.4-34.0
  *Participants (n)*                                         
  Baseline                                                   222
  3 months                                                   209
  1 year                                                     197
  2 years                                                    194
  3 years                                                    187
  5 years                                                    167 (75.2 %)

Where figures do not total 222 people or 100%, there are internal drop outs.

###### 

Questionnaire ratings at baseline, 3 months, 1-3 years and 5 years.

  QLQ C-30 scale                            n ^[a](#T2F2){ref-type="table-fn"}^   Mean   SEM    p-value (ANOVA)
  ----------------------------------------- ------------------------------------- ------ ------ ---------------------------------------
  **Physical functioning**                                                                      
  Baseline                                  197                                   96.3   0.73   
  3 months                                  204                                   94.9   0.8    
  1 year                                    197                                   95.1   0.80   
  2                                         194                                   95.3   0.71   
  3                                         187                                   94.4   0.77   
  5 years                                   166                                   93.9   0.89   0.109
  **Role functioning**                                                                          
  Baseline                                  199                                   92.2   1.41   
  3 months                                  206                                   91.3   1.3    
  1 year                                    195                                   94.5   1.18   
  2                                         192                                   95.8   0.95   
  3                                         186                                   93.4   1.12   
  5 years                                   166                                   94.5   1.09   0.227
  **Emotional functioning**                                                                     
  Baseline                                  199                                   78.9   1.37   
  3 months                                  206                                   87     1.11   0.000[\*](#T2F1){ref-type="table-fn"}
  1 year                                    196                                   89.8   1.08   
  2                                         193                                   89.1   1.16   
  3                                         186                                   89.2   1.07   
  5 years                                   166                                   90.9   1.06   0.000[\*](#T2F1){ref-type="table-fn"}
  **Cognitive functioning**                                                                     
  Baseline                                  199                                   90.1   1.03   
  3 months                                  208                                   90.4   0.85   
  1 year                                    197                                   90     0.97   
  2                                         193                                   89.7   0.99   
  3                                         186                                   89.4   1.01   
  5 years                                   167                                   90.3   1.09   0.979
  **Social functioning**                                                                        
  Baseline                                  196                                   92.4   1.16   
  3 months                                  208                                   86.3   1.31   0.001[\*](#T2F1){ref-type="table-fn"}
  1 year                                    196                                   88.1   1.42   
  2                                         192                                   91     1.19   
  3                                         186                                   90.8   1.64   
  5 years                                   165                                   92.2   1.22   0.003[\*](#T2F1){ref-type="table-fn"}
  **QOL, Global health status**                                                                 
  Baseline                                  198                                   78.1   1.43   
  3 months                                  208                                   77     1.37   
  1 year                                    196                                   79.6   1.34   
  2                                         191                                   81.6   1.19   
  3                                         185                                   81.2   1.3    
  5 years                                   165                                   80.4   1.47   0.273
  **Fatigue**                                                                                   
  Baseline                                  199                                   10.3   1.17   
  3 months                                  205                                   12.2   1.09   
  1 year                                    194                                   11     1.07   
  2                                         192                                   12.1   1.15   
  3                                         186                                   12.8   1.16   
  5 years                                   166                                   12.5   1.22   0.328
  **Nausea and vomiting**                                                                       
  Baseline                                  199                                   1.3    0.47   
  3 months                                  205                                   0.7    0.25   
  1 year                                    195                                   0.5    0.2    
  2                                         192                                   1.2    0.4    
  3                                         186                                   1      0.35   
  5 years                                   166                                   2.3    0.76   0.074
  **Pain**                                                                                      
  Baseline                                  199                                   9.5    1.38   
  3 months                                  207                                   7.5    1.19   
  1 year                                    196                                   7.1    1.22   
  2                                         193                                   7.7    1.13   
  3                                         186                                   6.5    1.14   
  5 years                                   166                                   7.7    1.24   0.482
  **Single item scales Dyspnoea**                                                               
  Baseline                                  198                                   12.1   1.51   
  3 months                                  205                                   10.4   1.24   
  1 year                                    195                                   12.5   1.37   
  2                                         192                                   12.2   1.38   
  3                                         184                                   12.3   1.5    
  5 years                                   165                                   13.1   1.48   0.389
  **Sleep**                                                                                     
  Baseline                                  199                                   17.3   1.81   
  3 months                                  205                                   13.8   1.56   
  1 year                                    195                                   13.7   1.67   
  2                                         192                                   13.7   1.72   
  3                                         186                                   14.3   1.6    
  5 years                                   166                                   14.7   1.81   0.324
  **Appetite**                                                                                  
  Baseline                                  199                                   2.5    1.71   
  3 months                                  204                                   1.3    0.45   
  1 year                                    195                                   1.9    0.55   
  2                                         192                                   3.0    0.81   
  3                                         186                                   1.8    0.61   
  5 years                                   166                                   1.4    0.59   0.272
  **Constipation**                                                                              
  Baseline                                  199                                   2.8    0.85   
  3 months                                  206                                   2.9    0.83   
  1 year                                    196                                   4.1    0.95   
  2                                         193                                   2.2    0.94   
  3                                         186                                   3.6    0.91   
  5 years                                   166                                   4.4    1.08   0.416
  **Diarrhoea**                                                                                 
  Baseline                                  198                                   1.0    0.80   
  3 months                                  206                                   4.3    0.88   
  1 year                                    196                                   4.0    0.82   
  2                                         193                                   5.0    1.01   
  3                                         186                                   4.8    0.97   
  5 years                                   166                                   3.8    1.12   0.894
  **Economy**                                                                                   
  Baseline                                  195                                   1.0    0.48   
  3 months                                  208                                   3.5    0.84   0.028[\*](#T2F1){ref-type="table-fn"}
  1 year                                    196                                   2.4    0.70   
  2                                         191                                   1.6    0.51   
  3                                         186                                   2.2    0.66   
  5 years                                   166                                   2.0    0.68   0.387[\*](#T2F1){ref-type="table-fn"}
                                                                                                
  PR-25 scale                               N                                     Mean   SEM    p-value (ANOVA)
                                                                                                
  **Functional scales Sexual activity**                                                         
  Baseline                                  165                                   48.4   2.25   
  3 months                                  189                                   43.4   3.36   
  1 year                                    174                                   38.7   2.21   
  2                                         180                                   39.1   2.02   
  3                                         169                                   39.5   2.46   
  5 years                                   149                                   40.4   4.26   0.252
  **Sexual functioning**                                                                        
  Baseline                                  124                                   84.1   1.67   
  3 months                                  105                                   42.9   2.25   0.000[\*](#T2F1){ref-type="table-fn"}
  1 year                                    102                                   47.6   2.86   
  2                                         112                                   50.6   2.34   
  3                                         103                                   50.2   2.5    
  5 years                                   88                                    56.7   2.8    0.000[\*](#T2F1){ref-type="table-fn"}
  **Symptom scales Urinary symptoms**                                                           
  Baseline                                  170                                   17.1   1.26   
  3 months                                  195                                   18.8   1.01   
  1 year                                    183                                   15.1   0.92   
  2                                         186                                   14.8   1.05   
  3                                         176                                   15.6   1.23   
  5 years                                   162                                   16.2   1.28   0.286[\*](#T2F1){ref-type="table-fn"}
  **Bowel symptoms**                                                                            
  Baseline                                  123                                   4.1    0.91   
  3 months                                  166                                   2.1    0.38   
  1 year                                    146                                   3      0.55   
  2                                         147                                   4.3    0.74   
  3                                         143                                   5.8    1.46   
  5 years                                   132                                   4.5    0.91   0.057
  **Hormone treatment- related symptoms**                                                       
  Baseline                                  166                                   6.2    0.72   
  3 months                                  188                                   11     0.64   0.000[\*](#T2F1){ref-type="table-fn"}
  1 year                                    176                                   11.8   0.91   
  2                                         179                                   11.1   0.85   
  3                                         173                                   11.8   0.86   
  5 years                                   149                                   9.5    0.85   0.006[\*](#T2F1){ref-type="table-fn"}
  **Single item scale Incontinence aid**                                                        
  Baseline                                  10                                    13.3   5.44   
  3 months                                  80                                    22.9   3.23   
  1 year                                    43                                    17.1   4.2    
  2                                         39                                    17.1   3.21   
  3                                         40                                    11.7   3.28   
  5 years                                   38                                    11.4   2.89   0.058

When significant ANOVA-test, the Bonferroni post hoc analysis was used

Internal drop-outs: EORTC QLQ C-30, 1-26; PR 25, 27- 212.

###### 

EORTC QLQ C-30 functional and single item variables impact on overall quality of life at 5 years following treatment. Multiple regression analysis (n=162).

                                                        95 % C-I^[1)](#T3F3){ref-type="table-fn"}^ for Odds ratio   
  ---- ------- ---------------------------------------- ----------------------------------------------------------- -------
  PF   0.11    0.21                                     -0.10                                                       0.44
  RF   0.00    0.99                                     -0.25                                                       0.23
  EF   0.27    \<0.00[\*](#T3F4){ref-type="table-fn"}   0.16                                                        0.59
  CF   -0.05   0.51                                     -0.32                                                       0.15
  SF   0.24    \<0.01[\*](#T3F4){ref-type="table-fn"}   0.11                                                        0.48
  FA   -0.10   0.26                                     -0.35                                                       0.09
  NV   -0.29   \<0.00[\*](#T3F4){ref-type="table-fn"}   -0.86                                                       -0.29
  PA   -0.18   \<0.02[\*](#T3F4){ref-type="table-fn"}   -0.41                                                       0.04
  DY   -0.14   0.07                                     -0.30                                                       0.01
  SL   0.14    0.51                                     -0.00                                                       0.24
  AP   0.08    0.25                                     -0.15                                                       0.53
  CO   -0.11   0.12                                     -0.32                                                       0.04
  DI   0.04    0.60                                     -0.15                                                       0.25
  FI   0.10    0.16                                     -0.08                                                       0.50

Dependent variable Quality of Life

R Square 46.1%

C-I^1^) Confidence interval

Sig. value \<0.05

Collinearity statistics, Tolerance 0.45 -- 0.80, VIF 1.52 -- 2.25

###### 

PR 25 variables impact on quality of life at five years following treatment. Multiple regression analysis (n=81).

                                                                              95 % C-I^[1)](#T4F2){ref-type="table-fn"}^ for Odds ratio   
  -------------------------- ------- ---------------------------------------- ----------------------------------------------------------- -------
  Sexual activity            0.18    0.91                                     -0.00                                                       0.09
  Sexual functioning         0.04    0.72                                     -0.17                                                       0.17
  Urinary functioning        -0.11   0.32                                     -0.36                                                       0.12
  Hormone related symptoms   -0.38   \<0.00[\*](#T4F3){ref-type="table-fn"}   -0.90                                                       -0.20

Dependent variable Quality of Life. Independent variables PRBOW, PRAID excluded due to drop outs R Square 23.5%. Adjusted R for small sample 19.4%.

C-I, Confidence interval

Sig. value \<0.05

Collinearity statistics, Tolerance 0.70 -- 0.96, VIF 1.42 -- 1.04

###### 

Likelihood of early *vs* late symptoms. Logistic regression analysis (0=baseline, 1=5 years) (n=222).

                                                               95 % C-I^[1)](#T5F3){ref-type="table-fn"}^ for Odds ratio   
  ---- ------ ------- ---------------------------------------- ----------------------------------------------------------- ------
  PF   0.98   2.40    0.12                                     0.95                                                        1.01
  RF   1.02   2.60    0.11                                     0.97                                                        1.04
  EF   1.08   41.86   \<0.00[\*](#T5F5){ref-type="table-fn"}   1.06                                                        1.11
  CF   0.99   1.21    0.26                                     0.96                                                        1.01
  SF   0.97   6.94    \<0.00[\*](#T5F5){ref-type="table-fn"}   0.95                                                        0.99
  QL   0.99   0.01    0.94                                     0.98                                                        1.02
  FA   1.04   9.09    \<0.00[\*](#T5F5){ref-type="table-fn"}   1.01                                                        1.06
  NV   1.03   1.69    0.19                                     0.99                                                        1.08
  PA   0.99   1.67    0.20                                     0.97                                                        1.01
  DY   1.01   0.20    0.65                                     0.98                                                        1.02
  SL   1.00   0.00    0.99                                     0.99                                                        1.01
  AP   0.99   0.40    0.52                                     0.95                                                        1.01
  CO   1.02   3.52    0.06                                     1.00                                                        1.05
  DI   0.99   0.26    0.61                                     0.97                                                        1.02
  FI   1.00   0.24    0.88                                     0.97                                                        1.04

PF-FI categorical variables (EORTC QLQ C-30)

Hosmer and Lemeshow goodness-of-fit test, p= 0.189

C-I, Confidence interval

Cox & Snell R square, 0.230, Nagelkerke R square, 0.306

Significant values p=\<0.05
